PRS-060: First-in-Class Inhaled IL4Ra Antagonist for Asthma

Candidate	Targets	Indication	Partner	Our Commercial Rights	Discovery	Preclinical	IND- enabling	Phase I	Phase Ib/IIa
PRS-060	IL4Ra	Asthma		U.S. Co-commercialization	Discovery Phase completed	Pre-Clinical Phase completed	IND-enabling Phase in progress	Phase 1 not started	Phase 2 not started

PRS-060 serves to treat moderate to severe asthma through direct delivery of a potent IL4Ra-targeting Anticalin protein to the lungs. A large proportion of asthma patients suffer from a disorder in the Th2 pathway, where the cytokines IL-4 and IL-13 play an important role. Both cytokines signal via IL4Ra, making IL4Ra a cornerstone intervention point. PRS-060 differentiates from antibodies addressing this pathway through inhaled delivery directly into the lungs, potentially resulting in convenience, efficacy and safety benefits. Local delivery allows for very low doses, likely also resulting in a significant cost of goods advantage over systemically delivered antibodies. This program currently is in IND-enabling studies and the initiation of a first-in-man clinical trial is anticipated around the middle of 2017. The program is partnered with AstraZeneca, with Pieris retained co-development and co-commercialization options in the USA.